The partners will develop vaccine candidates based on Themis’ measles virus vector-based platform. The vaccines are designed to deliver multiple selected antigens directly to macrophages and dendritic cells, thus triggering a specific immune response to the selected antigens . . .
![Milestone fees due to Seattle Genetics could total $200 million.[Markus Schnatmann-Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/March22_2011_15327090_GreenWhiteAntibodyAttachingtoAntigens_SeatlleADCcollabAbbott1409924912-100x70.jpg "Abbott to Use Seattle Genetics’ Antibody-Drug Conjugate Platform for $8M Up Front")